Literature DB >> 15616339

Effect of antacids and ranitidine on the single-dose pharmacokinetics of fosamprenavir.

Susan L Ford1, Mary B Wire, Yu Lou, Katherine L Baker, Daniel S Stein.   

Abstract

Single doses of MAALOX TC and ranitidine were administered separately with 1,400 mg of fosamprenavir (FPV). MAALOX TC decreased the area under the concentration-time curve from 0 to 24 h (AUC(0-24)) for plasma amprenavir (APV) by 18% and the maximum concentration of drug in serum (C(max)) by 35%; the plasma APV concentration at 12 h (C(12)) increased by 14%. Ranitidine at 300 mg decreased the AUC(0-24) for plasma APV by 30% and C(max) by 51%; C(12) was unchanged. FPV may be coadministered with antacids without concern and without separation in dosing; however, caution is recommended when FPV is coadministered with histamine(2)- receptor antagonists or proton pump inhibitors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15616339      PMCID: PMC538899          DOI: 10.1128/AAC.49.1.467-469.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  10 in total

1.  Comparative studies of two-times-daily versus three-times-daily indinavir in combination with zidovudine and lamivudine.

Authors:  D W Haas; E Arathoon; M A Thompson; R de Jesus Pedro; J E Gallant; D E Uip; J Currier; L M Noriega; D S Lewi; P Uribe; L Benetucci; P Cahn; D Paar; A C White; A C Collier; C H Ramirez-Ronda; C Harvey; M O Chung; D Mehrotra; J Chodakewitz; B Y Nguyen
Journal:  AIDS       Date:  2000-09-08       Impact factor: 4.177

2.  Toxicity, efficacy, plasma drug concentrations and protease mutations in patients with advanced HIV infection treated with ritonavir plus saquinavir. Swiss HIV Cohort Study.

Authors:  P Lorenzi; S Yerly; K Abderrakim; M Fathi; O T Rutschmann; J von Overbeck; D Leduc; L Perrin; B Hirschel
Journal:  AIDS       Date:  1997-10       Impact factor: 4.177

3.  Ordered accumulation of mutations in HIV protease confers resistance to ritonavir.

Authors:  A Molla; M Korneyeva; Q Gao; S Vasavanonda; P J Schipper; H M Mo; M Markowitz; T Chernyavskiy; P Niu; N Lyons; A Hsu; G R Granneman; D D Ho; C A Boucher; J M Leonard; D W Norbeck; D J Kempf
Journal:  Nat Med       Date:  1996-07       Impact factor: 53.440

4.  Effervescent and standard formulations of ranitidine--a comparison of their pharmacokinetics and pharmacology.

Authors:  R G Watson; B T Johnston; T C Tham; K Kersey
Journal:  Aliment Pharmacol Ther       Date:  1996-12       Impact factor: 8.171

5.  A 24-week open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir).

Authors:  D S Stein; D G Fish; J A Bilello; S L Preston; G L Martineau; G L Drusano
Journal:  AIDS       Date:  1996-05       Impact factor: 4.177

6.  Indinavir concentrations and antiviral effect.

Authors:  E P Acosta; K Henry; L Baken; L M Page; C V Fletcher
Journal:  Pharmacotherapy       Date:  1999-06       Impact factor: 4.705

7.  Pharmacologic characteristics of indinavir, didanosine, and stavudine in human immunodeficiency virus-infected children receiving combination therapy.

Authors:  C V Fletcher; R C Brundage; R P Remmel; L M Page; D Weller; N R Calles; C Simon; M W Kline
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

8.  Pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor amprenavir after multiple oral dosing.

Authors:  B M Sadler; C Gillotin; Y Lou; D S Stein
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

9.  Six-week randomized controlled trial to compare the tolerabilities, pharmacokinetics, and antiviral activities of GW433908 and amprenavir in human immunodeficiency virus type 1-infected patients.

Authors:  Robin Wood; Keikawus Arasteh; Hans-Jürgen Stellbrink; Eugenio Teofilo; François Raffi; Richard B Pollard; Joseph Eron; Jane Yeo; Judith Millard; Mary Beth Wire; Odin J Naderer
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

10.  Preclinical pharmacology and pharmacokinetics of GW433908, a water-soluble prodrug of the human immunodeficiency virus protease inhibitor amprenavir.

Authors:  Eric S Furfine; Christopher T Baker; Michael R Hale; David J Reynolds; Jo A Salisbury; Andy D Searle; Scott D Studenberg; Dan Todd; Roger D Tung; Andrew Spaltenstein
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

  10 in total
  8 in total

Review 1.  Clinically significant drug interactions with antacids: an update.

Authors:  Ryuichi Ogawa; Hirotoshi Echizen
Journal:  Drugs       Date:  2011-10-01       Impact factor: 9.546

2.  Pharmacokinetic interaction between darunavir boosted with ritonavir and omeprazole or ranitidine in human immunodeficiency virus-negative healthy volunteers.

Authors:  Vanitha J Sekar; Eric Lefebvre; Els De Paepe; Tine De Marez; Martine De Pauw; Wim Parys; Richard M W Hoetelmans
Journal:  Antimicrob Agents Chemother       Date:  2007-01-08       Impact factor: 5.191

3.  Effect of omeprazole on the plasma concentrations of indinavir when administered alone and in combination with ritonavir.

Authors:  Hiba L Tappouni; John C Rublein; Brian J Donovan; Stephanie B Hollowell; Hsiao-Chuan Tien; Sherene S Min; Dickens Theodore; Naser L Rezk; Philip C Smith; Melanie N Tallman; Ralph H Raasch; Angela D M Kashuba
Journal:  Am J Health Syst Pharm       Date:  2008-03-01       Impact factor: 2.637

Review 4.  Fosamprenavir : clinical pharmacokinetics and drug interactions of the amprenavir prodrug.

Authors:  Mary Beth Wire; Mark J Shelton; Scott Studenberg
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

5.  A pharmacokinetic study of etravirine (TMC125) co-administered with ranitidine and omeprazole in HIV-negative volunteers.

Authors:  Monika Schöller-Gyüre; Thomas N Kakuda; Goedele De Smedt; Hilde Vanaken; Marie-Paule Bouche; Monika Peeters; Brian Woodfall; Richard M W Hoetelmans
Journal:  Br J Clin Pharmacol       Date:  2008-04-25       Impact factor: 4.335

Review 6.  Drug interactions between HIV protease inhibitors and acid-reducing agents.

Authors:  Ronald W Falcon; Thomas N Kakuda
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

7.  Parallel monitoring of plasma and intraluminal drug concentrations in man after oral administration of fosamprenavir in the fasted and fed state.

Authors:  Joachim Brouwers; Jan Tack; Patrick Augustijns
Journal:  Pharm Res       Date:  2007-04-19       Impact factor: 4.200

8.  Antiretroviral drug interactions: overview of interactions involving new and investigational agents and the role of therapeutic drug monitoring for management.

Authors:  R Chris Rathbun; Michelle D Liedtke
Journal:  Pharmaceutics       Date:  2011-10-21       Impact factor: 6.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.